Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p131 | (1) | ICCBH2019

Use of intravenous pamidronate in pediatric acute lymphoblastic leukemia patients with osteonecrosis (ON) results in reduced pain and improved radiologic outcome of ON lesions: Long- term follow-up over 15-years

Miettunen Paivi , Moorani Vijay , Haider Seemab , Stephenson Seamus , Stephenson Chloe , Anderson Ronald

Background: Osteonecrosis (ON) has emerged as a debilitating complication of acute pediatric lymphoblastic leukemia (pALL), with severe pain and poor functional outcome. ON affecting weight bearing joints may eventually need arthroplasty, with large juxta-articular lesions being at highest risk. Intravenous Pamidronate (IV-PAM) is postulated to reduce pain and prevent joint collapse in ON.Objective: To study if IV-PAM was effective in 1) preventing joint...

ba0007p132 | (1) | ICCBH2019

A prospective study of 17 consecutive pediatric patients with chronic non-bacterial osteomyelitis treated with intravenous pamidronate over a 15 year period at a single center reveals excellent clinical and radiologic outcome initially and after flare

Miettunen Paivi , Stephenson Chloe , Stephenson Seamus , Wei Xing-Chang

Objectives: To describe a prospective series of pediatric CNO (pCNO) patients treated with IV-Pamidronate (IV-PAM) regarding effect on 1) pain, 2) Whole Body Magnetic Resonance Imaging (WBMRI) documented inflammation; 3) Spinal CNO and 4) bone turnover.Methods: All pCNO patients (<18 years at diagnosis) with WBMRI confirmed active CNO who were treated with IV-PAM between 2003–2018. IV-PAM: First dose 0.5 mg/kg; subsequently 1 mg/kg (max dose 60 ...